Pharmaceutical firm Strides Arcolab holds a 12% stake in the biosimilar developer after investing $9m in 2014.

The Belgium-based stem cell therapy developer, which is backed by investors including Gri-Cel and Novartis, has filed to go public in the US.

The eye disease treatment developer has raised $48m in funding from investors including Santen Pharmaceutical, which is also a research partner.

The antibody-based drug developer has raised $77m in financing, with Merck leading its $30m series B round in 2014.

The Google Ventures-backed genome editing technology company has raised $163m in equity across two rounds.

Novo and Roche-backed Corvus has raised more than $108m in venture funding in just over a year and will spend the IPO proceeds on developiing its immuno-oncology therapies.

Sheffield University spinout Diurnal began trading on Aim, on Christmas eve, raising $44.6m.

Novo and AbbVie-backed Reata plans to use the proceeds to fund a series of clinical trials for its hypertension treatments.

The oncology-focused biotechnology company, backed by Fidelity Management and Research, withdrew a previous filing in January 2015.

The household services booking app has been backed by Tencent since its $650,000 seed round in 2013, and has filed to list on NEEQ.